ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients
May 27, 2021French biotech company Abivax has revealed positive topline results from a Phase IIb study of its investigational oral drug candidate ABX464 in ulcerative colitis (UC) patients. -
Abivax Chosen to Deliver ABX464 Oral Presentation at Digestive Disease Week (DDW) Conference in the U.S.
March 06, 2019Abivax (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biopharmaceutical company harnessing the immune system to develop novel treatments for patients with inflammatory/autoimmune, and viral diseases and cancer...
Pharma Sources Insight January 2025
